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OBJECTIVES: Surgical management of Haemorrhoidal Disease includes Milligan-
Morgan (MM) haemorrhoidectomy and Stapled Haemorrhoidopexy (PPH). Scope of 
work was to compare HTA Reports for PPH vs. MM (especially cost and budget 
impact analyses) for two Italian Regions: Lombardia and Toscana. METHODS: Lit-
erature search; identiﬁcation of the surgical course (intervention, hospital admission) 
and global course (clinical evaluation, surgical phase, follow-up) at the local hospital 
level; micro-costing for PPH vs. MM at 3 hospitals per Region; comparison of direct 
medical costs, reimbursement tariffs and budgetary impact in 2008 Euro values. 
RESULTS: PPH surgical pattern generates costs to Hospitals of a2,306 and a2,177/
case, respectively in Lombardia and Toscana; MM surgery costs are a1558 and 
a1277/case, respectively. Higher unitary costs of personnel and operating theatre in 
Lombardia drive higher surgical intervention costs, irrespective of procedure type. 
Whereas hospital admission costs were similar for PPH (a698 vs a638), the gap 
between Lombardia and Toscana widens for MM hospitalization costs (a812 vs a638), 
because of longer length of stay in full admission setting. The Lombardia DRG158 
tariff (a1209) is not sufﬁcient to recap costs of both alternatives, whilst the Toscana 
tariff (a1400) is remunerative only for MM, but not when applying higher levels 
of operating theatre unit cost. The global course generates costs of a2532 (PPH-
 Lombardia) and a2400 (PPH-Toscana) vs a1781 (MM-Toscana) and a1527 
(MM-Toscana). Sensitivity analyses on literature data conﬁrmed the robustness of 
basecase results. Budget impact analysis, based on regional statistics for haemorrhoidal 
surgery and suggested extra-tariffs for PPH, estimated the need for additional 
funding ranging 1.7%–16% for Lombardia and 2.2%–20.4% for Toscana, over the 
current Regional expenditure. CONCLUSIONS: Analysis of management courses 
showed the inadequacy of current regional funding for PPH and MM. Current region-
alization of the Italian NHS prompts for implementation of HTA at the Regional 
level.
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OBJECTIVES: To assess the association between compliance with antipsychotic drug 
therapy and mental health-related hospitalization in people with schizophrenia. 
METHODS: A nested case-control study using the Quebec Health Insurance Board 
databases. The source cohort was made of people with schizophrenia who initiated 
an antipsychotic treatment between January 1, 2000 and March 31, 2007. Cases were 
cohort members who were hospitalized for a mental health-related problem during 
their follow-up period. Five matched (for sex, age and year of treatment initiation) 
controls were selected using density sampling method thus allowing a control’s 
 observation period to equal its case’s period. Compliance was assessed using the 
medication possession ratio (MPR). A paired multivariate logistic regression model 
was used to calculate adjusted odds ratios (OR). Co-variates included: mental health 
co-morbidities, patient characteristics at treatment initiation; antipsychotics and other 
drugs used as well as health services used during the observation period and current 
use of any antipsychotic at the end of the observation period. RESULTS: A total of 
2429 cases were identiﬁed and matched to 11,988 controls. Compared to individuals 
with a MPR q 80%, those with a MPR q 40% and 80% (OR: 1.4; 95% conﬁdence 
interval (CI): 1.1–1.7) and those with a MPR  40% (OR: 1.9; CI: 1.5–2.4) were more 
likely to be hospitalized. Were also more likely to be hospitalized: past antipsychotic 
users (OR: 1.4; CI: 1.1–1.7), those with low SES (OR: 1.3; CI: 1.2–1.4)) and those 
with more medical visits (2nd tertile: OR: 1.5; CI: 1.3–1.7, 3rd tertile: OR: 2.0; 
CI: 1.8–2.3). Likewise, having bipolar disorder (OR: 1.7; CI: 1.4–2.0) as well as 
having another psychosis diagnosis (OR: 1.4; CI: 1.2–1.7) increase the likelihood of 
hospitalization. CONCLUSIONS: Among people with schizophrenia, compliance 
with antipsychotic treatment does inﬂuence the risk of hospitalization.
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OBJECTIVES: This study aims to determine since when the evidence on the two most 
important groups of antidepressants SSRI and TCA could be valued as a sufﬁcient 
basis for medical decision making regarding the preference for one of them. Further-
more, it was analyzed whether the utilization of SSRI in Germany from this point 
onward was adequate and to what extent health gains might have been foregone due 
to a limited use of SSRI. METHODS: To determine since when the beneﬁcial effect 
of SSRI was known, cumulative metaanalyses of RCT derived from systematic reviews 
were conducted. The evidence base was considered as established, when signiﬁcant 
(5%-level) results favoring SSRI or TCA regarding two main outcome criteria (anti-
depressive efﬁcacy and treatment termination due to side-effects) were observed. 
 Utilization ﬁgures for SSRI and epidemiological estimates were taken from published 
sources. RESULTS: Findings on n  4031 patients of 31 studies on the antidepressive 
efﬁcacy from 1983 to 2001 could be considered. The cumulative metaanalysis showed 
no signiﬁcant difference between SSRI and TCA regarding the antidepressive efﬁcacy 
(RR 0.05; 95%-KI 0.01–0.12). On the other hand, in the course of time, SSRI were 
consistently superior regarding unwanted side-effects since 1985 (RR 0.69; 95%-KI 
0.62–0.77). CONCLUSIONS: Regarding the comparison of the efﬁcacy of both sub-
stance groups, our ﬁndings are in line with the common clinical appraisal. The supe-
riority of SSRI in terms of lower rates of treatment termination has become known 
in the mid 1980s. The analysis of the utilization data suggests a considerable delay in 
the consequences of this appreciation for routine care. Factors like cost considerations 
and lack in knowledge dissemination might have contributed to this phenomenon. 
Limitations of the present analysis are primarily associated with uncertainties of 
 epidemiological estimates and the application of study results to the entire patient 
population.
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OBJECTIVES: Schizophrenia is a complex and heterogeneous psychiatric disorder        
with usual onset in early adulthood leading to a lifetime of morbidity and chronic 
disability that affects a person’s ability to perceive, think and feel. The disease hetero-
geneity and chronic course presents signiﬁcant challenges for realistic economic model-      
ling. We present a cost-effectiveness model of schizophrenia applied to the UK, which 
overcomes the limitations of previous modelling techniques. METHODS: Given the 
heterogeneous and progressive nature of schizophrenia, accurate modelling needs to 
capture patient history and, in particular, the complex interactions between treatment 
discontinuation and relapse, and the impact of past relapses on the risk of future 
relapse. For these reasons, a discrete event simulation (DES) model was built compar-
ing the cost-effectiveness of olanzapine long-acting injection (OLAI) against risperi-
done long-acting injection (RLAI). The model considered a real-world patient 
population utilising data from real-world sources such as open-label studies rather 
than randomised controlled trials. An indirect comparison was used to calculate 
relapse and treatment discontinuation rates. Key outcomes of interest included relapse, 
discontinuation, treatment switching, side effects, quality-adjusted life years, and 
treatment and resource use costs. RESULTS: The DES model captured outcomes that 
other modelling techniques would struggle to achieve. Among these were patient time 
on/off different treatments, occurrence of side effects including post-injection syn-
drome, and the number of relapses and treatment discontinuations. By modelling a 
real-world patient population, the evaluation generated patient-level ﬁndings directly 
relevant to clinical practice and accentuated the beneﬁts of OLAI for reducing the risk 
of treatment discontinuation and in turn relapses. CONCLUSIONS: Key modelling 
challenges for schizophrenia include capturing patient history and time-dependent 
variables such as relapse and discontinuation. Real-world modelling to inform deci-
sion-making is growing in importance, and therefore requires the application of 
advanced simulation techniques.
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OBJECTIVES: The acetylcholinesterase inhibitors (ChEIs) donepezil, rivastigmine and 
galantamine are recommended for symptomatic treatment of mild to moderate 
Alzheimer’s Disease (AD). Despite AChEI efﬁcacy being demonstrated in randomised 
clinical trials (RCTs), this study design has limited validity in relation to real-world 
patient care. Observational studies of routine patient care can be valuable sources of 
adverse event (AE) data in chronic conditions such as AD. A systematic review was 
undertaken to compare the safety of the AChEIs in treating AD in routine clinical 
care. METHODS: Cochrane Library, MEDLINE, and EMBASE searches were con-
ducted together with searches of selected bibliographies and conference proceedings 
to identify head-to-head, non-randomised AChEI studies. Two reviewers indepen-
dently extracted data from relevant articles. RESULTS: Twelve studies (N  6 prospec-
tive; N  6 retrospective) met the pre-speciﬁed inclusion criteria. Due to study design 
heterogeneity, a narrative data analysis was conducted. Four studies reporting total 
AE data found consistently fewer AEs in donepezil versus other AChEI patients, the 
difference being statistically signiﬁcant in the largest study (N  5462; p  0.001). In 
three of four studies, fewer donepezil-treated patients withdrew due to AEs compared 
to patients receiving the other two AChEIs, with a statistically signiﬁcant difference 
